Tag Archives | clinical diagnostics

Rayno Dx and Tools: Abbott (ABT) Buys Alere (ALR) For $5.8B Expanding Point-of-Care Diagnostics Platforms

Abbott Laboratories Acquires Alere (ALR) -Stock Soars 45% At Market Opening Alere Product Line Offers Synergies and Boosts Global Diagnostics Presence 2015 Revenues of Alere Are Estimated in $2.5B Range So Deal is About 2.3X Sales Alere (ALR) has a broad-based product line in rapid point-of-care diagnostics with tests for infectious disease such as influenza […]

Continue Reading 0

Rayno Molecular Diagnostics and Tools Update: CPHD, HOLX, PACB

Dominant Trend is Precision Medicine and Molecular Medicine Lackluster revenue growth has tempered stock gains since Q3 earnings reports however the sector has always had good investment potential due to M&A and new products. Stocks are up from October lows. Our last update was in November and re-iterated the “Precision Medicine” trend which integrates targeted therapies […]

Continue Reading 0

Biotech Rally Underway Trying to Overcome Gloomy Macro Data…Update-1

Update 11/16 PM Biotech Rally Underperforms Energy up 2.99% and Telecom up 1.81% The S&P and Dow rallied past Paris attack and terrorism concerns after an early morning stall. Biotechs underperformed weighed down by the Clovis Oncology (CLVS) NDA delay. The IBB was up 0.39% in a choppy session. Among the losers were mid-caps awaiting […]

Continue Reading 0

Large Cap Biotech Stocks Get Traction From Revenue Growth…Update-1

10/29/15 Update Large Cap Biotechs Update Amgen (AMGN) Revenues Grow 14%, beats street. 2016 Revenues guided to ~$22B, flattish revenue growth with higher EPS $10.35-$10.75. 2015 PEG=1.80, P/S=5.94, Div. 1.94% Rayno Biopharmaceutical Portfolio Large Caps up 2.6% YTD, IBB up 8% YTD REGN up 37%, GILD up 16%, AMGN up o.6% ABBV ALXN BIIB RHHBY […]

Continue Reading 0

Rayno Life Sciences Diagnostics and Tools Update: Volatile Stocks and Slower Growth Ahead

10/7/15 Update…Still in No Man’s Land…Nothing to Do See recent posts on bear market in biotech. We need to wait for Q3 earnings to find trades and longer term value in Dx and Tools. Most stocks in the sector have been hit hard since August. ———- Slower Growth with Same Themes: Sequencing (NGS) and Molecular […]

Continue Reading 0

Slower Growth in Diagnostics Stocks Except for NexGen Sequencing and Molecular

New technologies in diagnostics and tools are driving growth: NexGen sequencing, molecular and “point-of-care” testing platforms and veterinary testing. M&A and consolidation should continue. The sector is a laggard due to slowing  sales and earnings growth vs forecasts. Rayno Clinical Diagnostics Portfolio Update We initiated coverage of Clinical Diagnostic and Life Science Tools stocks in […]

Continue Reading 0

Rayno Dx and Tools: Update EXAS

Valuation Does Matter If Revenue Growth Slows Last week we posted a YTD summary of our diagnostics and tools focus stocks. Three stocks that are up over one year but have been weak in 2015. We said that revenue guidance and technicals will be important for: Exact Sciences (EXAS), Genomic Health (GHDX) and Neogen (NEOG). […]

Continue Reading 0

Rayno Dx and Tools Portfolio: CSII HOLX ILMN TMO Stellar Performers

Solid  earnings reports-All of Our Picks Are Strong Holds But Strong Dollar a Factor in 2105 Cardiovascular Systems (CSII) Stock Soars 15% On Strong Revenues Interventional treatments for cardiovascular disease Q2 Revenues soared 38% to $44.7M compared to previous fiscal Q2 2014. Fiscal Q2 2105 loss was $5.3M or (0.17) per share. Hologic (HOLX) Beats […]

Continue Reading 0

JPMorgan Conference #3: Emerging Clinical Dx Companies- AXDX, GNMK

Next Generation Clinical Diagnostic Systems We sat in on presentations for two innovative clinical diagnostic companies that have platform products serving big potential markets. Although it may be early to buy these stocks now they should be on your watch list for the new product revenue ramp up. Solutions For The Global Challenge of Drug […]

Continue Reading 0

2015 Biotech Stock Preview: Rhythms of the “PermaBull”

2015: Another Good Year Unless “Something Happens” Life Science stocks had another big year in 2014 up 48% tracking gains for the overall healthcare sector up 35%. Over 10 years the return is 300%! The move up was not a straight line as there were  two major corrections in April 2014 after the Q1 “bio-bubble” […]

Continue Reading 0

Rayno Dx and Tools 2014 Performance YTD: ABAX EXAS ILMN PACB SQNM

Many Big Winners Are Among  Rayno Diagnostics and Tools Stocks in 2014 Abaxis (ABAX) up 46%  A major “Point of Care” (POC) Dx Player in veterinary and human markets. Exact Sciences (EXAS) up 135%  An emerging Dx player with non-invasive, DNA based test for colon cancer. Illumina Inc. (ILMN) up 68%  Leading provider of DNA […]

Continue Reading 0

Rayno Life Science Stocks: Stealth Rally Ignited By Apple..Update 1

Update -1 Choppy Market Continues..Faux Rally on Wednesday? NASDAQ at 4561 Down 0.66% 1-Reiterate profit taking in Achillion (ACHN), Exact Sciences (EXAS) and  Illumina (ILMN). 2-XBI treading water at 160 since August 26. Bull market intact. 3-Recent early August new buys ran up then fell back: CLDX, KPTI and PACB. 4-ACHN momentum is easing at […]

Continue Reading 0

Rayno Life Science: Trading Notes End of August

As we move into a heavier trading period watch your portfolio for changes as volume picks up. Here are some of our long term portfolio winners where you can take profits: Exact Sciences (EXAS) short squeeze took it to $22. Illumina (ILMN) triple to at $180. Here are a few laggard stocks with bullish momentum: […]

Continue Reading 0

Rayno DX and Tools Mid Year Review and AACC Update: ABAX, ILMN, HOLX, TMO.. Update-2

Update -2 Aug. 1 Draft Guidance on LDTs Coming from FDA in 60 Days: Tests Must Be Validated More regulation coming means greater development costs and potential time delays for clinical tests in development and currently marketed as LDTs . Presumably LDT tests will be allowed to remain on the market. Potential intermediate term impact […]

Continue Reading 0

Rayno Life Sciences: First Half Stock Performance Part 2-ILMN, SQNM

Rayno Diagnostics and Tools-Sequencing Rules Diagnostics and Tools stocks tracked biotech stocks during the huge moves in January/February and sold off until the April bottom. However stocks that are more revenue and earnings driven -Cardiovascular Systems(CSII) and Quidel (QDEL)- did not recover to former highs. Sequenom  (SQNM) is a leader in non-invasive pre-natal tests such […]

Continue Reading 0